When faced with the possibility of missed findings, would patients generally agree to consuming oral contrasts?
Most outpatients would accept drinking oral contrast material if it has diagnostic benefit, according to a study published in the Journal of the American College of Radiology.
Researchers from University of Michigan in Ann Arbor performed a prospective survey to determine how patients valued the use of oral contrast material when undergoing abdominopelvic CT.
A total of 218 patients completed the survey, in which the subjects were given a hypothetical choice to not drink oral contrast. Eighty-nine percent of the subjects (193 patients) stated that they would always drink the contrast for fear of missing an important finding, and only 2% (5 patients) stated that they would never drink it regardless of risk.
Nine percent (20 patients) said that the decision to drink oral contrast would depend on the level of risk, with 8% (18 patients) indicating that they would accept a 0.01% to 1.00% risk for missing an important finding if they did not have to drink oral contrast.
The researchers also asked about the tolerability of the oral contrast; 55% (120 patients) rated the oral contrast taste as tolerable and 10% (21 patients) rated it bad or terrible.
Thirty-six subjects experienced concern or unease when they learned that they had to drink oral contrast:
• 8 minimal concern or unease
• 15 mild
• 10 moderate
• 3 extreme
Thirty-six patients experienced oral contrast–induced nausea or abdominal discomfort:
• 10 minimal
• 15 mild
• 10 moderate
• 1 extreme
The researchers concluded that most patients will drink oral contrast if it has any diagnostic benefit.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.